Evidence map›Paper›PMID 30014466›Full record

ArticleThe Journal of pathology2018

Reduced expression of the RNA-binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27

Chongtae Kim, Da Eun Jeong, Sungeun Heo, Eunbyul Ji, Jun Gi Rho, Myeongwoo Jung, Sojin Ahn, Ye-Jin Kim, Yong-Sung Kim, Suk Woo Nam and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Chongtae KimDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Da Eun JeongDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Sungeun HeoDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Eunbyul JiDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Jun Gi RhoDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Myeongwoo JungDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Sojin AhnDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Ye-Jin KimDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Yong-Sung KimDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Suk Woo NamDepartment of Pathology, College of Medicine, The Catholic University of Korea, Seoul, South Korea.ORCID 0000-0001-5767-8291
Rohit N KulkarniDepartment of Islet Cell and Regenerative Biology, Joslin Diabetes Center and Department of Medicine, Harvard Medical School and Harvard Stem Cell Institute, Boston, MA, USA.
Kyoung Bun LeeDepartment of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Eun Kyung LeeDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Wook KimDepartment of Molecular Science and Technology, Ajou University, Suwon, South Korea.ORCID 0000-0002-7701-4684
Ajou University · KRCatholic University of Korea · KRJoslin Diabetes Center · USSeoul National University · KR

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
Role of IGF-1 and Insulin Receptors Beta-Cell SurvivalR01DK067536 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 2004 to 2026
$8.0M
Role of SerpinB1 in beta cell growthR01DK103215 · NIDDK · JOSLIN DIABETES CENTER · PI KULKARNI, ROHIT N. · 2014 to 2018
$2.6M
NIDDK NIH HHS P30 DK036836NIDDK NIH HHS R01 DK067536NIDDK NIH HHS R01 DK103215
6 · The paper itself

Abstract

For the majority of patients diagnosed with pancreatic neuroendocrine tumors (NETs), there is significant malignant potential with a poor prognosis; however, the molecular abnormalities and pathogenesis of pancreatic NETs have not been firmly established. Here, we report that loss of expression of the RNA-binding protein HuD correlates with low p27

Indexed as

3' Untranslated Regions5' Untranslated RegionsAdultAgedAnimalsBinding SitesBiomarkers, TumorCarcinoma, NeuroendocrineCell CycleCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p27Down-RegulationELAV-Like Protein 4FemaleGene Expression Regulation, Neoplastic3' Untranslated Regions5' Untranslated RegionsBiomarkers, TumorCDKN1B protein, humanCdkn1b protein, mouseCyclin-Dependent Kinase Inhibitor p27ELAVL4 protein, humanElavl4 protein, mouseELAV-Like Protein 4MicroRNAsMIRN30b microRNA, humanMirn30d microRNA, mouseReceptor, InsulinHuDp27Kip1pancreatic neuroendocrine tumorprognosisRNA-binding protein

Identifiers

PMID30014466
PMCPMC6150781
OpenAlexW2884374591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.